Where is Coldzyme located?

Coldzyme is headquartered in United Kingdom.

Where does Coldzyme rank among its competitors?

Coldzyme ranks 30th amongst 37 active competitors, of which 8 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was ARTCLINE, which secured $3.95M in Sep, 2026.

Who are the top competitors of Coldzyme?

Coldzyme's top competitors include Cerus, Amferia and Aethlon Medical. Among them, ARTCLINE secured the most recent funding round in September, 2026.

Coldzyme - 2026 Company Profile & Competitors

Company Details

Manufacturer of medical mouth spray to block cold virus infection. This device functions by forming a protective barrier in the throat to capture and disable viruses upon contact. It assists in alleviating respiratory symptoms and reducing illness duration when applied at the early stages of infection. The product utilizes marine enzymes and is designed for use by adults and children to provide protection in various environments.

Website: coldzyme.co.uk
Social
Part Of

Key Metrics

Location

United Kingdom

Stage

Unfunded

Ranked

30^th among 37 active competitors

Similar Companies

Cerus & 39 more

View Coldzyme's full profile

Coldzyme has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Coldzyme include Cerus, Amferia and Aethlon Medical. Here is the list of Top 10 competitors of Coldzyme, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Cerus 1991, Concord (United States), Public	Provider of pathogen inactivation technology for blood center or hospital blood bank	-	MidCap Financial, Apollo Investment Corporation ... & 4 others	61/100
2nd	Amferia 2018, Gothenburg (Sweden), Series B	Developer of an anti-infective technology	$7.56M	Almi Invest, Chalmers Ventures & 6 others	57/100
3rd	Aethlon Medical 1999, San Diego (United States), Public	Immunotherapeutic device company combating cancer and life-threatening viral infections	-	NIH, HHS	56/100
4th	Cel-Sci 1983, Vienna (United States), Public	Developer of immunotherapy products for the treatment of cancer and infectious diseases	-	Alpha Capital Partners, Midsummer Capital ... & 7 others	53/100
5th	ARTCLINE 2007, Germany, Series A	Developer of immune cell-based extracorporeal therapies for intensive care medicine	$8.71M	-	51/100
6th	Ondine Biomedical 1999, Vancouver (Canada), Public	Developer of anti-infective therapies for a broad spectrum of bacterial, viral and fungal infections	$798K	Springboard Enterprises	49/100
7th	Z-App Kit 2007, Hafnarfjordur (Iceland), Unfunded	Developer of a amplifier and app for killing pathogenic microorganisms	-	-	45/100
8th	PATH EX 2016, Nashville (United States), Series A	Developing blood-cleansing device to remove pathogens from circulating blood	$5M	IAG Capital Partners, TMC Venture Fund & 9 others	40/100
9th	3Oe Scientific 2010, Carmel (United States), Series A	Provider of smart solutions to manage pathogen infections	$3.71M	-	34/100
10th	ToeFX 2016, Hamilton (Canada), Seed	Company discovering and developing treatment of toenail fungus (onychomycosis)	$30K	Accelerator Centre, The Forge	34/100
30th	Coldzyme United Kingdom, Unfunded	Manufacturer of medical mouth spray to block cold virus infection	-	-	16/100